These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 23747051)

  • 1. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.
    Richards D; Kocs DM; Spira AI; David McCollum A; Diab S; Hecker LI; Cohn A; Zhan F; Asmar L
    Eur J Cancer; 2013 Sep; 49(13):2823-31. PubMed ID: 23747051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
    Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
    Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
    Pinto C; Di Fabio F; Siena S; Cascinu S; Rojas Llimpe FL; Ceccarelli C; Mutri V; Giannetta L; Giaquinta S; Funaioli C; Berardi R; Longobardi C; Piana E; Martoni AA
    Ann Oncol; 2007 Mar; 18(3):510-7. PubMed ID: 17164226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
    Deenen MJ; Meulendijks D; Boot H; Legdeur MC; Beijnen JH; Schellens JH; Cats A
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1285-95. PubMed ID: 26499900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction.
    Richards D; McCollum D; Wilfong L; Sborov M; Boehm KA; Zhan F; Asmar L
    Ann Oncol; 2008 Jan; 19(1):104-8. PubMed ID: 17897959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
    Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
    J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
    Shah MA; Jhawer M; Ilson DH; Lefkowitz RA; Robinson E; Capanu M; Kelsen DP
    J Clin Oncol; 2011 Mar; 29(7):868-74. PubMed ID: 21189380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
    Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
    Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.
    Brodowicz T; Ciuleanu TE; Radosavljevic D; Shacham-Shmueli E; Vrbanec D; Plate S; Mrsic-Krmpotic Z; Dank M; Purkalne G; Messinger D; Zielinski CC
    Ann Oncol; 2013 Jul; 24(7):1769-1777. PubMed ID: 23559149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
    Pant S; Patel M; Kurkjian C; Hemphill B; Flores M; Thompson D; Bendell J
    Cancer Invest; 2017 Aug; 35(7):463-472. PubMed ID: 28662341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
    Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
    J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience.
    Petrioli R; Francini E; Roviello F; Marrelli D; Fiaschi AI; Laera L; Rossi G; Bianco V; Brozzetti S; Roviello G
    Cancer Chemother Pharmacol; 2015 May; 75(5):941-7. PubMed ID: 25743995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001.
    Hejna M; Raderer M; Zacherl J; Ba-Ssalamah A; Püspök A; Schmidinger M; Pluschnig U; Brodowicz T; Zielinski CC
    Anticancer Drugs; 2008 Jun; 19(5):535-9. PubMed ID: 18418220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.
    Douillard JY; Zemelka T; Fountzilas G; Barone C; Schlichting M; Heighway J; Eggleton SP; Srimuninnimit V
    Clin Colorectal Cancer; 2014 Mar; 13(1):14-26.e1. PubMed ID: 24370353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.
    Hickish T; Cassidy J; Propper D; Chau I; Falk S; Ford H; Iveson T; Braun M; Potter V; Macpherson IR; Finnigan H; Lee C; Jones H; Harrison M
    Eur J Cancer; 2014 Dec; 50(18):3136-44. PubMed ID: 25441408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE; Hartmann JT; Hofheinz R; Homann N; Rethwisch V; Probst S; Stoehlmacher J; Clemens MR; Mahlberg R; Fritz M; Seipelt G; Sievert M; Pauligk C; Atmaca A; Jäger E
    Ann Oncol; 2008 Nov; 19(11):1882-7. PubMed ID: 18669868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
    Wöll E; Greil R; Eisterer W; Bechter O; Fridrik MA; Grünberger B; Zabernigg A; Mayrbäurl B; Russ G; Dlaska M; Obrist P; Thaler J
    Anticancer Res; 2011 Dec; 31(12):4439-43. PubMed ID: 22199312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.